



Product Information

Product ID G7440

CAS No. 871700-17-3

Chemical Name

Synonym Trametinib, JTP-74057

Formula C₂₆H₂₃FIN₅O₄

Formula Wt. 615.39

Melting Point


Purity ≥98%

Solubility DMSO (10 mg/ml)
Water Insoluble
Ethanol Insoluble

Store Temp -20°C

Ship Temp Ambient

Description GSK-1120212 inhibits MEK1/2 and is currently in clinical trials as a potential treatment for melanoma. GSK-1120212 exhibits anticancer chemotherapeutic activity, upregulating p27 expression and inhibiting growth in colorectal cancer cells and suppressing tumor growth in colorectal cancer xenografts.



Pricing and Availability

Bulk quantities available upon request

Product ID	Size	List Price
G7440	5 mg	\$78.80
G7440	25 mg	\$102.90
G7440	100 mg	\$183.80

References Hartsough EJ, Basile K, Aplin AE. Beneficial Effects of RAF Inhibitor in Mutant BRAF Splice Variant-expressing Melanoma. Mol Cancer Res. 2014 Feb 11. [Epub ahead of print]. PMID: 24520098.

Kim KB, Kefford R, Pavlick AC, et al. Phase II study of the MEK1/MEK2 inhibitor Trametinib in patients with metastatic BRAF-mutant cutaneous melanoma previously treated with or without a BRAF inhibitor. J Clin Oncol. 2013 Feb 1;31(4):482-9. PMID: 23248257.

Yamaguchi T, Kakefuda R, Tajima N, et al. Antitumor activities of JTP-74057 (GSK1120212), a novel MEK1/2 inhibitor, on colorectal cancer cell lines in vitro and in vivo. Int J Oncol. 2011 Jul;39(1):23-31. PMID: 21523318.

Caution: This product is intended for laboratory and research use only. It is not for human or drug use.